BR112022004534A2 - Anticorpos de domínio único direcionados contra lilrb2 - Google Patents

Anticorpos de domínio único direcionados contra lilrb2

Info

Publication number
BR112022004534A2
BR112022004534A2 BR112022004534A BR112022004534A BR112022004534A2 BR 112022004534 A2 BR112022004534 A2 BR 112022004534A2 BR 112022004534 A BR112022004534 A BR 112022004534A BR 112022004534 A BR112022004534 A BR 112022004534A BR 112022004534 A2 BR112022004534 A2 BR 112022004534A2
Authority
BR
Brazil
Prior art keywords
directed against
single domain
domain antibodies
antibodies directed
lilrb2
Prior art date
Application number
BR112022004534A
Other languages
English (en)
Inventor
Julien Caumartin
Lise Hunault
Maria Loustau
Pierre Langlade-Demoyen
Original Assignee
Invectys SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Invectys SAS filed Critical Invectys SAS
Publication of BR112022004534A2 publication Critical patent/BR112022004534A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)

Abstract

anticorpos de domínio único direcionados contra lilrb2. a presente invenção refere-se a anticorpos de domínio único (sdabs) direcionados contra membro 2 da subfamília b do receptor semelhante a imunoglobulina leucocitária (lilrb2) e composições farmacêuticas compreendendo os mesmos.
BR112022004534A 2019-09-20 2020-09-18 Anticorpos de domínio único direcionados contra lilrb2 BR112022004534A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19306148 2019-09-20
PCT/EP2020/076198 WO2021053199A1 (en) 2019-09-20 2020-09-18 Single-domain antibodies directed against lilrb2

Publications (1)

Publication Number Publication Date
BR112022004534A2 true BR112022004534A2 (pt) 2022-06-07

Family

ID=68654426

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022004534A BR112022004534A2 (pt) 2019-09-20 2020-09-18 Anticorpos de domínio único direcionados contra lilrb2

Country Status (11)

Country Link
US (1) US20230235050A1 (pt)
EP (1) EP4031572A1 (pt)
JP (1) JP2022548764A (pt)
KR (1) KR20220128332A (pt)
CN (1) CN115066435A (pt)
AU (1) AU2020351274A1 (pt)
BR (1) BR112022004534A2 (pt)
CA (1) CA3154450A1 (pt)
IL (1) IL291506A (pt)
MX (1) MX2022003365A (pt)
WO (1) WO2021053199A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114805580B (zh) * 2022-06-28 2022-09-06 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
CN115975029A (zh) * 2022-06-28 2023-04-18 北京科诺信诚科技有限公司 靶向人lilrb2的纳米抗体及其应用
WO2024022462A1 (zh) * 2022-07-29 2024-02-01 盛禾(中国)生物制药有限公司 一种抗ilt4的单域抗体及其应用
WO2024041315A1 (en) * 2022-08-22 2024-02-29 Antengene (Hangzhou) Biologics Co., Ltd. Novel anti-lilrb2 antibodies and uses thereof
WO2024108568A1 (zh) * 2022-11-25 2024-05-30 深圳先进技术研究院 抗人类白细胞抗原-g纳米抗体及其制备方法与应用
CN117169505A (zh) * 2023-09-05 2023-12-05 中日友好医院(中日友好临床医学研究所) 一种结直肠癌治疗靶点和血清标志物及其应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007285695B2 (en) 2006-08-18 2012-05-24 Ablynx N.V. Amino acid sequences directed against IL-6R and polypeptides comprising the same for the treatment of diseases and disorders associated with IL-6-mediated signalling
WO2008142165A1 (en) * 2007-05-24 2008-11-27 Ablynx N.V. Amino acid sequences directed against growth factor receptors and polypeptides comprising the same for the treatment of diseases and disorders associated with growth factors and their receptors
WO2011117423A1 (en) 2010-03-26 2011-09-29 Ablynx N.V. Immunoglobulin single variable domains directed against cxcr7
US20160200815A1 (en) * 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
AU2018389111A1 (en) * 2017-12-22 2020-06-18 Jounce Therapeutics, Inc. Antibodies to LILRB2
EP3740224A4 (en) * 2018-01-18 2022-05-04 Adanate, Inc. ANTI-LILRB ANTIBODIES AND THEIR USES

Also Published As

Publication number Publication date
MX2022003365A (es) 2022-08-22
JP2022548764A (ja) 2022-11-21
IL291506A (en) 2022-05-01
CA3154450A1 (en) 2021-03-25
WO2021053199A1 (en) 2021-03-25
AU2020351274A1 (en) 2022-05-05
US20230235050A1 (en) 2023-07-27
CN115066435A (zh) 2022-09-16
KR20220128332A (ko) 2022-09-20
EP4031572A1 (en) 2022-07-27

Similar Documents

Publication Publication Date Title
BR112022004534A2 (pt) Anticorpos de domínio único direcionados contra lilrb2
BR112018075626A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco anticorpo
BR112021026517A2 (pt) Degradadores de irak e usos dos mesmos
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
BR112021013824A2 (pt) Receptores de antígeno quiméricos gprc5d e células que expressam os mesmos
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
BR112018075653A2 (pt) anticorpos anti-b7-h3 e conjugados anticorpo fármaco
BR112022011651A2 (pt) Degradadores de irak e usos dos mesmos
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
BR112018074185A2 (pt) 3-oxo-2,6-difenil-2,3-di-hidropiridazina-4-carboxamidas
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
BR112018075651A2 (pt) anticorpos anti-cd98 e conjugados anticorpo fármaco
BR112018075649A2 (pt) anticorpos anti-b7-h3 e conjugados de fármaco de anticorpo
BR112019022321A2 (pt) Tcr e peptídeos
BR112018074032A2 (pt) composições e métodos relacionados a construtos de fc manipulados
BR112022003147A2 (pt) Novos anticorpos anti-cldn18.2
BR112019002734A2 (pt) tratamento e remissão virológica sustentada de infecção por hiv por anticorpos para cd4 em pacientes estabilizados por haart
CY1125348T1 (el) Νεοι ανταγωνιστες υποδοχεων β2 βραδυκινινης
BR112021024938A2 (pt) Anticorpos de receptor 1 de peptídeo natriurético e métodos de uso
BR112018075630A2 (pt) anticorpos anti-cd98 e conjugados de fármaco de anticorpo
BR112021016056A2 (pt) Anticorpos de claudina 6 e usos dos mesmos
BR112018076215A2 (pt) partículas e composições de nicotina
MA47370A (fr) Dérivés bis-hétéroaryliques en tant que modulateurs de l'agrégation des protéines
BR112021011124A2 (pt) Anelossomos e métodos de uso